Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke

Stroke

Volumn 40, Issue 4, 2009, Pages 1482-1489

  McCarthy, Claudia A ^a   Vinh, Antony ^a   Callaway, Jennifer K ^b   Widdop, Robert E ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AT2receptors; Cerebral infarction; Cerebral ischemia; Neuroprotection; SHR; Stroke

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ENDOTHELIN 1; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; SUPEROXIDE; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN INFARCTION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; CONSCIOUSNESS; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BLOOD PRESSURE; CELL SURVIVAL; CEREBRAL INFARCTION; CONSCIOUSNESS; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 2; STROKE; SUPEROXIDES; VASODILATOR AGENTS;

EID: 65249180615     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.531509     Document Type: Article

References (39)

1. Mclnnes G. The expanding role angiotensin receptors blockers in the management of the elderly hypertensive. Curr Med Res Opin. 2003;19:452-453.
2. Chapman N, Huxley R, Anderson C, Bousser G, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. Stroke. 2004;35:116-121.
3. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener H, Dominiak P. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34: 1699-1703.
4. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurological outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab. 2004;24:467-474.
5. Nishimura Y, Ito T, Saavedra J. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31:2478-2486.
6. Ito T, Yamakawa H, Bregonzio C, Terron J, Falcon-Neri A, Saavedra J. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II ATI antagonist. Stroke. 2002;33:2297-2303.
7. Zhou J, Pavel J, Macova M, Yu Z, Imboden H, Ge L, Nishioku T, Dou J, Delgiacco E, Saavedra J. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke. 2006;37:1271-1276.
8. Ando H, Zhou J, Macova M, Imboden H, Saavedra J. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004;35: 1726-1731.
9. Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;20:2391-2399.
10. Lou M, Blume A, Zhao Y, Golhlke P, Deuschl G, Herdegen T, Culman J. Sustained blockade of brain ATI receptors before and after focal cerebral ischemia alleviates neurological deficits and reduces neuronal injury, apoptosis and inflammatory responses in the rat. J Cereb Blood Flow Metab. 2004;24:536-547.
11. Zhou J, Ando H, Macova M, Dou J, Saavedra J. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab. 2005;25:878-886.
12. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume AK, E. Unger T, Zimmermann M, Seidel K, Dirnagl U, Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005;19:617-619.
13. Lucius R, Gallinat S, Rosenstiel P, Unger T, Sievers J. The angiotensin II type 2 receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661-670.
14. Laflamme L, Gasparo M, Gallo J, Payet M, Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. J Biol Chem. 1996;271:22729-22735.
15. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdengen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kB. FASEB J. 2003;17:2094-2096.
16. Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. Sciatic nerve tran-section evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res. 1998;57:111-122.
17. Widdop R, Jones E, Hannan R, Gaspari T. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-824.
18. Jones E, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol. 2004;37:1023-1030.
19. Lu Q, Zhu Y-Z, Wong PT-H. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuro-report. 2005;16:1963-1967.
20. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843-848.
21. Mogi M, Li J-M, Iwanami J, Min L-J, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension. 2006;48:141-148.
22. Thone-Reineke C, Steckelings U, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens. 2006;24: S115-S121.
23. Sharkey J, Ritchie I, Kelly P. Perivascular microapplication of endothe-lin-1: a new model of focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab. 1993;13:865-871.
24. Callaway JK, Knight MJ, Watkins DJ, Beart PM, Jarrott B. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1 induced middle cerebral artery occlusion in conscious rats. Stroke. 1999;30:2704-2712.
25. Roulston CL, Callaway JK, Jarrott B, Woodman OL, Dusting GJ. Using behaviour to predict stroke severity in conscious rats: post-stroke treatment with 3',4'-dihydroxyflavonol improves recovery. Eur J Pharmacol. 2008;584:100-110.
26. Metz GAD, V. Schwab ME, van de Meent H. The effect of unilateral pyramidal tract section on hindlimb motor performance in rats. Behav Brain Res. 1998;96:37-46.
27. Callaway JK, Knight MJ, Watkins DJ, Beart PM, Jarrott B, Delaney PM. A novel, rapid, computerised method for quantification of neuronal damage in a rat model of stroke. J Neurosci Methods. 2000;102:53-60.
28. Osborne KA, Shigeno T, Balarsky AM, Ford I, McCulloch J, Teasdale GM, Graham DI. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1987; 50:402-410.
29. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells- implications in cardiovascular disease. Braz J Med Biol Res. 2004;37:1263-1273.
30. Roulston CL, Jarrott AB, Widdop R. Localization of AT2 receptors in the nucleus of the solitary tract of spontaneously hypertensive and Wistar Kyoto rats using [125I]CGP42112: upregulation of a non-angiotensin II binding site following unilateral nodose ganglionectomy. Brain Res. 2003;968:139-155.
31. Fisher M, Garcia J. Evolving stroke and the ischemic penumbra. Neurology. 1996;47:884-888.
32. Barber MN, Sampey DB, Widdop RE. AT2 receptor stimulation enhances antihypertensive effects of atl receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112-1116.
33. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by ATI receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821-830.
34. Roulston CL, Lawrence AJ, Jarrott B, Widdop RE. Non-angiotensin II [1251] CGP42112 binding is a sensitive marker of neuronal injury in brainstem following unilateral nodose ganglionectomy: comparison with markers for activated microglia. Neuroscience. 2004;127:753-767.
35. de Oliveira AM, Viswanathan M, Heemskerk FM, Correa FM, Saavedra JM. Specific, non-angiotensin, [125I]CGP 42112 binding sites in rat spleen macrophages. Biochem Biophys Res Commun. 1992;200:1049-1058.
36. Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, Yap EH, Lee HS, Wong PT. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport. 2000;11:1191-1194.
37. Kreisel SH, Bazner H, Hennerici MG. Pathophysiology of stroke rehabilitation: temporal aspects of neurofunctional recovery. Cerebrovasc Dis. 2006;21:6-17.
38. Miller AA, Dusting GJ, Roulston CL, Sobey CG. NADPH-oxidase activity is elevated in penumbral and non-ischemic cerebral arteries following stroke. Brain Res. 2006;1111:111-116.
39. Hamai M, Iwai M, Ide A, Tomochika H, Tomono Y, Mogi M, Horiuchi M. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology. 2006;51:822-828.